Company news
Theralase Technologies Inc. news in 2019
Theralase Technologies Inc.'s news releases, calls and decks from 2019, newest first.
Theralase Releases Third Quarter 2019 Financial Results and Company Update
November 29, 2019
Theralase Researchers Receive Recognition for Recent Scientific Publications
November 27, 2019
Theralase Announces Leadership Transition
October 31, 2019
Theralase Granted European Patent for Anti-Cancer Photo Dynamic Compounds
October 22, 2019
London Health Sciences Centre Launches as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
October 7, 2019
Theralase Files Investigational New Drug Application with the FDA
October 1, 2019
Patient Six Cancer-Free Eighteen Months After Single Anti-Cancer Treatment
September 30, 2019
Theralase Grants Stock Options
September 16, 2019
Theralase Annouces First Patient Treated in Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
September 4, 2019
Theralase Releases Second Quarter 2019 Financial Results and Company Update
August 29, 2019
Theralase Announces Closing of Prospectus Offering for Gross Proceeds of $17,250,000
August 22, 2019
Theralase Announces Pricing Of Prospectus Offering
August 1, 2019
Patient Five Cancer-Free Eighteen Months After Single Anti-Cancer Treatment
July 31, 2019
McGill University Health Centre Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
July 30, 2019
Theralase Enrolls First Patient into Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
July 29, 2019
Theralase Signs Agreement with Urology Organization to Provide US Clinical Study Sites for its Phase II Non Muscle Invasive Bladder Cancer Clinical Study
July 24, 2019
Theralase Receives Notice of Acceptance for Multiwavelength Photo Dynamic Therapy from Russian Patent Office
July 16, 2019
Theralase Releases 2019 Annual General Meeting Video Presentations
June 28, 2019
Regulatory Updates from Health Canada and US FDA
June 27, 2019
Theralase Files Prospectus for Offering of Units
June 26, 2019
Health Canada Approves Amended Clinical Trial Application
June 26, 2019
Theralase Brain Cancer Pre-Clinical Research Accepted for Publication
June 25, 2019
Theralase Releases Amended and Restated 1Q2019 Financial Statements
June 18, 2019
Voltaic Minerals Corp. Receives Conditional TSXV Acceptance for Binding Letter of Intent with 1146915 B.C. Ltd.
June 14, 2019
Theralase Releases 1Q 2019 Financial Statements
May 30, 2019
Theralase Granted Notice of Acceptance for PhotoDynamic Compounds by Chinese Patent Office
May 20, 2019
Theralase's 5th Annual Medical and Scientific Advisory Board Meeting Advances Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
May 13, 2019
Chinese Patent Office Issues Notice of Acceptance for Multiwavelength PhotoDynamic Therapy
May 7, 2019
Theralase's Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study Research Presented at the American Urological Association
May 6, 2019
Theralase Commences Phase II NMIBC Clinical Study
April 25, 2019
Theralase's Latest Scientific Research to be Presented at the 17th Annual International Photodynamic Association World Congress
April 22, 2019
Theralase(R) Releases 2018 Year End Audited Financial Statements
April 17, 2019
Patient Six Cancer-Free Twelve Months After Single Anti-Cancer Treatment
April 2, 2019
Theralase's Phase IB Clinical Study to be Presented at the 17(th) International Photodynamic Association World Congress
March 26, 2019
Theralase Granted United States Patent to Destroy Cancer Cells with X-Ray Activated Photo Dynamic Compounds
March 4, 2019
Theralase Named to 2019 TSX Venture 50(TM)
February 28, 2019
Theralase Announces Appointment of New Chief Executive Officers
February 25, 2019
Patient Five Cancer-Free Twelve Months After Single Anti-Cancer Treatment
January 31, 2019
Patient Six Cancer-Free at Nine Months After Single Anti-Cancer Treatment
January 30, 2019
Theralase(R) Completes $1.4 M Private Placement Equity Financing
January 9, 2019